Oxford Bioscience Partners

Yolia Health, based in Mexico City, specializes in developing innovative medical equipment aimed at preserving, restoring, and enhancing vision. The company has created The True Vision Treatment (TVT), a non-invasive solution designed to address common vision issues such as presbyopia, myopia, and hyperopia. TVT allows patients to self-administer treatment at home using a combination of customized contact lenses and specially formulated eye drops. After only five days of treatment, patients can typically cease using both the contact lenses and eye drops, as well as their reading glasses, for up to 12 months before requiring re-treatment. Notably, Yolia's approach not only corrects near vision but also improves distance vision, distinguishing it from other alternatives on the market. The company is actively seeking sophisticated investors and industry partners to further its mission.

CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.

Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.

Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.

Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.

Glori Energy is a development stage company focused on enhancing oil recovery from existing well reservoirs without the need for new drilling. The company's mission is to safely and efficiently extract billions of barrels of oil that are otherwise trapped. To achieve this, Glori partners with oil producers to implement the AEROTM (Activated Environment for Recovery of Oil) System, which significantly boosts oil production. This innovative system offers a cost-effective and environmentally friendly solution for recovering previously inaccessible oil, thereby facilitating its entry into the market.

CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

Adastra Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in developing innovative treatments for cancer. Founded in 2005 and previously known as Tragara Pharmaceuticals, the company is focused on creating proprietary medicines aimed at improving patient care in oncology. Among its key products is an oral multi-kinase inhibitor designed to inhibit critical cyclin-dependent kinases, which may enhance patient survival rates and overall quality of life. Adastra Pharmaceuticals is dedicated to advancing its portfolio of cancer therapies to meet the needs of healthcare professionals and patients alike.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

Molecular Biometrics, Inc. is a metabolomics company based in Norwood, Massachusetts, focused on developing non-invasive methodologies for assessing biological functions in health and disease, as well as for drug discovery and development. Established in 2005, the company leverages innovative metabolomic technologies to create molecular gastronomy kits. Its applications span various fields, including reproductive health, neurodegenerative diseases such as Alzheimer's and Parkinson's, maternal-fetal medicine, pulmonary metabolism and edema, and lactate metabolism. By applying its proprietary technology, Molecular Biometrics aims to enhance the understanding and treatment of complex health issues.

ImpactRx, Inc. is a promotion research organization serving the pharmaceutical industry in the United States. The company specializes in tracking and evaluating the effects of pharmaceutical promotions on physicians' prescribing behaviors. Utilizing its proprietary technology, ImpactRx collects and processes data regarding physicians' perceptions and activities, enabling pharmaceutical companies to assess and predict the effectiveness of their sales and marketing initiatives. The organization offers a variety of syndicated and semi-custom products focused on brand management, market research, sales management, managed care marketing, and oncology sales and marketing. These services support pharmaceutical and biotech companies in making informed decisions. Founded in 2000, ImpactRx is headquartered in Mount Laurel, New Jersey.

CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps designed for long-term partial circulatory support. Its innovative approach allows for a proactive and lower-risk treatment option that enhances a patient's natural heart function, potentially improving the quality of life for millions of individuals with chronic heart failure. The company's proprietary micro-pump platform enables these devices to be small enough for implantation in a manner similar to pacemakers, utilizing endovascular or minimally-invasive surgical techniques. CircuLite's technology aims to provide essential support for patients with failing hearts by supplementing their natural pumping capacity.

Cambrios Technologies Corporation specializes in developing and manufacturing advanced electronic materials, particularly electrodes made from silver nanowires. These materials simplify the manufacturing processes for electronic devices while enhancing their performance. The company's flagship product, ClearOhm, consists of silver nanowire coating materials that create transparent conducting layers on various substrates. This technology is applicable to a wide range of products, including touch screens, liquid crystal displays, e-paper, organic light-emitting diodes (OLED), and thin film photovoltaics. Founded in 2002 as Semzyme, Inc., the company rebranded to Cambrios Technologies Corporation in 2004 and is headquartered in Sunnyvale, California, with additional offices in Japan and Taiwan. Cambrios aims to leverage its nanostructured materials to improve the efficiency and capabilities of next-generation consumer devices.

Coherex Medical, Inc. specializes in the design, development, and marketing of catheter-based technologies aimed at treating structural heart defects. The company focuses on developing devices for patients with atrial fibrillation who are at risk for stroke, including an innovative closure system for the left atrial appendage (LAA) and a patent foramen ovale (PFO) closure system that promotes tissue in-growth for long-term closure. Founded in 2003 as Proximare, Inc., the company rebranded to Coherex Medical in 2006 and is headquartered in Salt Lake City, Utah. Coherex Medical serves both domestic and international markets, providing crucial treatment options for structural heart conditions. As of 2015, the company operates as a subsidiary of Biosense Webster, Inc.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Claros Diagnostics, Inc. develops innovative products aimed at transforming in-vitro medical diagnostic testing by making it accessible outside of laboratory settings. The company has created a handheld immunoassay system designed for point-of-care blood testing, which includes a portable analyzer and a disposable cassette capable of assessing multiple biomarkers. This system facilitates the testing of various medical conditions, including infectious diseases, cancer, and immune disorders, empowering both physicians and patients with timely diagnostic capabilities.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

Pathway Medical Technologies Inc. is a company that specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative products, including an atherectomy catheter designed to restore circulation in the peripheral arteries. This device effectively removes hard and soft plaque, calcium, thrombus, and fibrotic lesions from treatment sites, enhancing blood flow. Additionally, Pathway Medical Technologies offers a control pod that provides a user-friendly interface with keypad controls for seamless device operation, ensuring that patients receive safe and effective treatment for arterial conditions.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

LUCA Technologies is developing long-term, biotechnology-driven solutions to rising U.S. dependence on foreign energy sources. Addressing the $150 billion domestic natural gas market, the company is leveraging the ability of naturally occurring microorganisms to convert under-utilized domestic oil, organic-rich shale and coal resources to clean, renewable energy. The company initially expects to provide consulting services to existing energy producers, helping them to evaluate their current oil, organic-rich shale and gas holdings for the presence of natural Geobioreactors or the potential for Geobioreactor stimulation.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Molecular Biometrics, Inc. is a metabolomics company based in Norwood, Massachusetts, focused on developing non-invasive methodologies for assessing biological functions in health and disease, as well as for drug discovery and development. Established in 2005, the company leverages innovative metabolomic technologies to create molecular gastronomy kits. Its applications span various fields, including reproductive health, neurodegenerative diseases such as Alzheimer's and Parkinson's, maternal-fetal medicine, pulmonary metabolism and edema, and lactate metabolism. By applying its proprietary technology, Molecular Biometrics aims to enhance the understanding and treatment of complex health issues.

Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.

ZettaCore is at the forefront of molecular electronics, dedicated to creating advanced molecular materials tailored for the electronics industry. By utilizing innovative chemistry, the company enhances existing manufacturing processes, facilitating a shift towards improved performance while simultaneously reducing costs.

BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.

Laboratory Partners, Inc. provides clinical diagnostic testing services for healthcare providers, including both hospitals and private practices. Laboratory Partners, Inc. is based in Palo Alto, California.

HydroCision, Inc. is a medical device company based in North Billerica, Massachusetts, established in 1994. It specializes in the development and manufacturing of fluid jet surgical tools tailored for minimally invasive spine surgery. The company’s primary offerings include the SpineJet HydroDiscectomy System, which allows for the safe removal of tissue during discectomy procedures without thermal damage, and the TenJet System, designed for ultrasound-guided treatments of chronic tendon pain in various applications such as the shoulder and knee. HydroCision also provides the SpineJet Fusion System for preparing intervertebral disc spaces for graft implantation and the AlloJet system for debridement of donor bones. The company serves hospitals and physicians through its sales representatives, aiming to improve surgical outcomes by leveraging its proprietary water-jet technology. HydroCision was previously known as Surgijet Corporation until its name change in November 1996.

Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.

Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.

Courtagen Life Sciences, Inc. is a biotechnology company based in Woburn, Massachusetts, specializing in genetic testing services. The company provides a range of clinical genetic tests focused on neurological conditions, including developmental delay, intellectual disability, autism spectrum disorders, epilepsy, and mitochondrial disorders. Its offerings include comprehensive analyses such as epiSEEK Comprehensive and epiSEEK Focus, which assess genes associated with neurological function and seizure disorders, respectively. Additionally, Courtagen offers tests for drug metabolism related to epilepsy, as well as panels for neurodevelopmental and lysosomal storage disorders. The company also provides next generation sequencing services to support research in target discovery, clinical development, and companion diagnostics. Founded in 2003, Courtagen Life Sciences aims to empower physicians, families, and children affected by neurological disorders through advanced genetic insights.

Xencor, Inc. is a clinical-stage biopharmaceutical company headquartered in Monrovia, California, specializing in the discovery and development of engineered monoclonal antibodies and other protein therapeutics aimed at treating severe and life-threatening diseases. The company leverages its proprietary XmAb technology platform to create a range of antibody product candidates for various conditions, including cancer and autoimmune diseases. Notable candidates in its portfolio include XmAb5871 and AIMab7195, both targeting autoimmune disorders, and several bispecific antibodies currently in clinical trials, such as XmAb14045 for acute myeloid leukemia and plamotamab for B-cell malignancies. Additionally, Xencor is advancing therapies for neuroendocrine tumors and gastrointestinal stromal tumors, as well as developing preclinical bispecific antibodies for various cancers. The company generates revenue through research and development collaborations and licensing agreements with major pharmaceutical firms. Founded in 1997, Xencor is committed to addressing unmet medical needs through innovative therapeutic solutions.

LUCA Technologies is developing long-term, biotechnology-driven solutions to rising U.S. dependence on foreign energy sources. Addressing the $150 billion domestic natural gas market, the company is leveraging the ability of naturally occurring microorganisms to convert under-utilized domestic oil, organic-rich shale and coal resources to clean, renewable energy. The company initially expects to provide consulting services to existing energy producers, helping them to evaluate their current oil, organic-rich shale and gas holdings for the presence of natural Geobioreactors or the potential for Geobioreactor stimulation.

Paperspace is a cloud computing company that specializes in machine learning (ML) development. It offers a high-performance cloud platform for building, training, and deploying ML models, catering to individuals, startups, and enterprises. The platform provides a cloud-based personal computer accessible via any web browser, making cloud computing more accessible through simplicity, community-driven resources, and straightforward pricing. This enables users to iterate faster and collaborate on real-time prediction engines.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

Intechra, LLC is an electronics lifecycle management company based in Jackson, Mississippi, specializing in information technology asset disposition (ITAD), value recovery, and computer recycling services. The company assists businesses and government entities in retiring IT assets, such as personal computers, servers, and networking equipment, while ensuring compliance with federal privacy regulations and environmental laws. Intechra offers a range of services including data security, service plans, and computer remarketing, complemented by logistics support that features secured transport and chain of custody. The recycling services provided by Intechra cover various materials, including metals, circuit boards, and batteries, as well as plastic casings and storage media. Additionally, Intechra operates an online store where it sells laptops, personal computers, and computer parts. The company serves small and mid-sized businesses, cities, and educational institutions, and was formerly known as Recycled Computers International, LLC, when it was founded in 1987.

CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps designed for long-term partial circulatory support. Its innovative approach allows for a proactive and lower-risk treatment option that enhances a patient's natural heart function, potentially improving the quality of life for millions of individuals with chronic heart failure. The company's proprietary micro-pump platform enables these devices to be small enough for implantation in a manner similar to pacemakers, utilizing endovascular or minimally-invasive surgical techniques. CircuLite's technology aims to provide essential support for patients with failing hearts by supplementing their natural pumping capacity.

Coherex Medical, Inc. specializes in the design, development, and marketing of catheter-based technologies aimed at treating structural heart defects. The company focuses on developing devices for patients with atrial fibrillation who are at risk for stroke, including an innovative closure system for the left atrial appendage (LAA) and a patent foramen ovale (PFO) closure system that promotes tissue in-growth for long-term closure. Founded in 2003 as Proximare, Inc., the company rebranded to Coherex Medical in 2006 and is headquartered in Salt Lake City, Utah. Coherex Medical serves both domestic and international markets, providing crucial treatment options for structural heart conditions. As of 2015, the company operates as a subsidiary of Biosense Webster, Inc.

Nfocus Neuromedical, Inc. designs, develops, and markets endovascular neurosurgery solutions to cure intracranial aneurysms. The company offers revolutionary systems to treat neurovascular disease, including brain aneurysms. The company was formerly known as CardioVasc, Inc. and changed its name to Nfocus Neuromedical, Inc. in April 2007. The company was incorporated in 1997 and is based in Palo Alto, California. As of February 19, 2013, Nfocus Neuromedical, Inc. operates as a subsidiary of Covidien plc.

Cambrios Technologies Corporation specializes in developing and manufacturing advanced electronic materials, particularly electrodes made from silver nanowires. These materials simplify the manufacturing processes for electronic devices while enhancing their performance. The company's flagship product, ClearOhm, consists of silver nanowire coating materials that create transparent conducting layers on various substrates. This technology is applicable to a wide range of products, including touch screens, liquid crystal displays, e-paper, organic light-emitting diodes (OLED), and thin film photovoltaics. Founded in 2002 as Semzyme, Inc., the company rebranded to Cambrios Technologies Corporation in 2004 and is headquartered in Sunnyvale, California, with additional offices in Japan and Taiwan. Cambrios aims to leverage its nanostructured materials to improve the efficiency and capabilities of next-generation consumer devices.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.

Adastra Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in developing innovative treatments for cancer. Founded in 2005 and previously known as Tragara Pharmaceuticals, the company is focused on creating proprietary medicines aimed at improving patient care in oncology. Among its key products is an oral multi-kinase inhibitor designed to inhibit critical cyclin-dependent kinases, which may enhance patient survival rates and overall quality of life. Adastra Pharmaceuticals is dedicated to advancing its portfolio of cancer therapies to meet the needs of healthcare professionals and patients alike.

Claros Diagnostics, Inc. develops innovative products aimed at transforming in-vitro medical diagnostic testing by making it accessible outside of laboratory settings. The company has created a handheld immunoassay system designed for point-of-care blood testing, which includes a portable analyzer and a disposable cassette capable of assessing multiple biomarkers. This system facilitates the testing of various medical conditions, including infectious diseases, cancer, and immune disorders, empowering both physicians and patients with timely diagnostic capabilities.

CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps designed for long-term partial circulatory support. Its innovative approach allows for a proactive and lower-risk treatment option that enhances a patient's natural heart function, potentially improving the quality of life for millions of individuals with chronic heart failure. The company's proprietary micro-pump platform enables these devices to be small enough for implantation in a manner similar to pacemakers, utilizing endovascular or minimally-invasive surgical techniques. CircuLite's technology aims to provide essential support for patients with failing hearts by supplementing their natural pumping capacity.

HydroCision, Inc. is a medical device company based in North Billerica, Massachusetts, established in 1994. It specializes in the development and manufacturing of fluid jet surgical tools tailored for minimally invasive spine surgery. The company’s primary offerings include the SpineJet HydroDiscectomy System, which allows for the safe removal of tissue during discectomy procedures without thermal damage, and the TenJet System, designed for ultrasound-guided treatments of chronic tendon pain in various applications such as the shoulder and knee. HydroCision also provides the SpineJet Fusion System for preparing intervertebral disc spaces for graft implantation and the AlloJet system for debridement of donor bones. The company serves hospitals and physicians through its sales representatives, aiming to improve surgical outcomes by leveraging its proprietary water-jet technology. HydroCision was previously known as Surgijet Corporation until its name change in November 1996.

HydroCision, Inc. is a medical device company based in North Billerica, Massachusetts, established in 1994. It specializes in the development and manufacturing of fluid jet surgical tools tailored for minimally invasive spine surgery. The company’s primary offerings include the SpineJet HydroDiscectomy System, which allows for the safe removal of tissue during discectomy procedures without thermal damage, and the TenJet System, designed for ultrasound-guided treatments of chronic tendon pain in various applications such as the shoulder and knee. HydroCision also provides the SpineJet Fusion System for preparing intervertebral disc spaces for graft implantation and the AlloJet system for debridement of donor bones. The company serves hospitals and physicians through its sales representatives, aiming to improve surgical outcomes by leveraging its proprietary water-jet technology. HydroCision was previously known as Surgijet Corporation until its name change in November 1996.

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Solstice Neurosciences is a specialty biopharmaceutical company dedicated to the development, manufacturing, and marketing of biopharmaceutical products. Its primary product is Myobloc (rimabotulinumtoxinB) Injection, marketed in the U.S., and NeuroBloc (Botulinum Toxin Type B) Injectable Solution, available in select international markets. This product is the only botulinum toxin type B offered to healthcare providers and patients globally and is specifically indicated for treating cervical dystonia to alleviate severe abnormal head positions and associated pain. In addition to its pharmaceutical offerings, Solstice provides reimbursement and product support services and maintains MYOBLOC University, an online platform designed to enhance physician education through self-study resources and learning technologies.

Pathway Medical Technologies Inc. is a company that specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative products, including an atherectomy catheter designed to restore circulation in the peripheral arteries. This device effectively removes hard and soft plaque, calcium, thrombus, and fibrotic lesions from treatment sites, enhancing blood flow. Additionally, Pathway Medical Technologies offers a control pod that provides a user-friendly interface with keypad controls for seamless device operation, ensuring that patients receive safe and effective treatment for arterial conditions.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of small molecule drugs aimed at addressing unmet medical needs in central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, the company is best known for NUPLAZID (pimavanserin), which is approved for treating hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA is also advancing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive therapy for schizophrenia, both of which are currently in Phase III clinical trials. Additionally, the company is exploring the use of pimavanserin for major depressive disorder. ACADIA maintains subsidiaries in Sweden and Denmark and is focused on expanding its portfolio of drug candidates, seeking to discover innovative therapies for various neurological and psychiatric conditions.

Courtagen Life Sciences, Inc. is a biotechnology company based in Woburn, Massachusetts, specializing in genetic testing services. The company provides a range of clinical genetic tests focused on neurological conditions, including developmental delay, intellectual disability, autism spectrum disorders, epilepsy, and mitochondrial disorders. Its offerings include comprehensive analyses such as epiSEEK Comprehensive and epiSEEK Focus, which assess genes associated with neurological function and seizure disorders, respectively. Additionally, Courtagen offers tests for drug metabolism related to epilepsy, as well as panels for neurodevelopmental and lysosomal storage disorders. The company also provides next generation sequencing services to support research in target discovery, clinical development, and companion diagnostics. Founded in 2003, Courtagen Life Sciences aims to empower physicians, families, and children affected by neurological disorders through advanced genetic insights.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Hypnion is a neuroscience drug discovery and development company that specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness issues as well as circadian rhythm abnormalities. Founded in 2000 and based in Worcester, Massachusetts, Hypnion has developed a proprietary drug discovery platform known as SCORE-2004, which measures the effects of various drugs on sleep and wake parameters. The company has attracted attention in the pharmaceutical industry, culminating in its acquisition by Eli Lilly and Company.

FlowMedica is a medical device company that specializes in intravascular systems for Targeted Renal Therapy, addressing renal conditions linked to cardiovascular disease, cancer, and surgical procedures. The company's flagship products include the Benephit CV Infusion System, which allows physicians to deliver therapeutic agents directly into the renal arteries via an infusion catheter, while facilitating simultaneous coronary procedures through a single access site in the femoral artery. Additionally, FlowMedica offers the Benephit XTMini Infusion System, designed for bilateral infusion to the kidneys, particularly beneficial for patients with smaller vascular anatomies. By providing a targeted approach to renal therapy, FlowMedica's devices serve as an effective alternative to traditional systemic intravenous infusion methods, enabling precise delivery in various clinical scenarios.

BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.

Solstice Neurosciences is a specialty biopharmaceutical company dedicated to the development, manufacturing, and marketing of biopharmaceutical products. Its primary product is Myobloc (rimabotulinumtoxinB) Injection, marketed in the U.S., and NeuroBloc (Botulinum Toxin Type B) Injectable Solution, available in select international markets. This product is the only botulinum toxin type B offered to healthcare providers and patients globally and is specifically indicated for treating cervical dystonia to alleviate severe abnormal head positions and associated pain. In addition to its pharmaceutical offerings, Solstice provides reimbursement and product support services and maintains MYOBLOC University, an online platform designed to enhance physician education through self-study resources and learning technologies.

Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

Alantos Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule drugs targeting conditions such as osteoarthritis, inflammation, and type II diabetes. Established in 2002 and located in Cambridge, Massachusetts, the company specializes in innovative therapeutic approaches, including Dipeptidyl and Peptidase IV inhibitors. In addition to its core areas, Alantos explores various tissue remodeling pathways to address a range of medical issues, including rheumatoid arthritis, liver fibrosis, cardiovascular conditions, chronic wound healing, and cancer.

Pathway Medical Technologies Inc. is a company that specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative products, including an atherectomy catheter designed to restore circulation in the peripheral arteries. This device effectively removes hard and soft plaque, calcium, thrombus, and fibrotic lesions from treatment sites, enhancing blood flow. Additionally, Pathway Medical Technologies offers a control pod that provides a user-friendly interface with keypad controls for seamless device operation, ensuring that patients receive safe and effective treatment for arterial conditions.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of small molecule drugs aimed at addressing unmet medical needs in central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, the company is best known for NUPLAZID (pimavanserin), which is approved for treating hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA is also advancing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive therapy for schizophrenia, both of which are currently in Phase III clinical trials. Additionally, the company is exploring the use of pimavanserin for major depressive disorder. ACADIA maintains subsidiaries in Sweden and Denmark and is focused on expanding its portfolio of drug candidates, seeking to discover innovative therapies for various neurological and psychiatric conditions.

Cambrios Technologies Corporation specializes in developing and manufacturing advanced electronic materials, particularly electrodes made from silver nanowires. These materials simplify the manufacturing processes for electronic devices while enhancing their performance. The company's flagship product, ClearOhm, consists of silver nanowire coating materials that create transparent conducting layers on various substrates. This technology is applicable to a wide range of products, including touch screens, liquid crystal displays, e-paper, organic light-emitting diodes (OLED), and thin film photovoltaics. Founded in 2002 as Semzyme, Inc., the company rebranded to Cambrios Technologies Corporation in 2004 and is headquartered in Sunnyvale, California, with additional offices in Japan and Taiwan. Cambrios aims to leverage its nanostructured materials to improve the efficiency and capabilities of next-generation consumer devices.

CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps designed for long-term partial circulatory support. Its innovative approach allows for a proactive and lower-risk treatment option that enhances a patient's natural heart function, potentially improving the quality of life for millions of individuals with chronic heart failure. The company's proprietary micro-pump platform enables these devices to be small enough for implantation in a manner similar to pacemakers, utilizing endovascular or minimally-invasive surgical techniques. CircuLite's technology aims to provide essential support for patients with failing hearts by supplementing their natural pumping capacity.

FlowMedica is a medical device company that specializes in intravascular systems for Targeted Renal Therapy, addressing renal conditions linked to cardiovascular disease, cancer, and surgical procedures. The company's flagship products include the Benephit CV Infusion System, which allows physicians to deliver therapeutic agents directly into the renal arteries via an infusion catheter, while facilitating simultaneous coronary procedures through a single access site in the femoral artery. Additionally, FlowMedica offers the Benephit XTMini Infusion System, designed for bilateral infusion to the kidneys, particularly beneficial for patients with smaller vascular anatomies. By providing a targeted approach to renal therapy, FlowMedica's devices serve as an effective alternative to traditional systemic intravenous infusion methods, enabling precise delivery in various clinical scenarios.

Solexa engages in developing and commercializing genetic analysis technologies primarily in the United States and the United Kingdom. The company is developing and preparing Solexa Genome Analysis System, which performs DNA sequencing based on its proprietary reversible terminator Sequencing-by-Synthesis, chemistry, and Clonal Single Molecule Array technology. Its platform is designed to support a range of analyses, including whole genome resequencing, gene expression analysis, and small RNA analysis.

Courtagen Life Sciences, Inc. is a biotechnology company based in Woburn, Massachusetts, specializing in genetic testing services. The company provides a range of clinical genetic tests focused on neurological conditions, including developmental delay, intellectual disability, autism spectrum disorders, epilepsy, and mitochondrial disorders. Its offerings include comprehensive analyses such as epiSEEK Comprehensive and epiSEEK Focus, which assess genes associated with neurological function and seizure disorders, respectively. Additionally, Courtagen offers tests for drug metabolism related to epilepsy, as well as panels for neurodevelopmental and lysosomal storage disorders. The company also provides next generation sequencing services to support research in target discovery, clinical development, and companion diagnostics. Founded in 2003, Courtagen Life Sciences aims to empower physicians, families, and children affected by neurological disorders through advanced genetic insights.

Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.

Cambrios Technologies Corporation specializes in developing and manufacturing advanced electronic materials, particularly electrodes made from silver nanowires. These materials simplify the manufacturing processes for electronic devices while enhancing their performance. The company's flagship product, ClearOhm, consists of silver nanowire coating materials that create transparent conducting layers on various substrates. This technology is applicable to a wide range of products, including touch screens, liquid crystal displays, e-paper, organic light-emitting diodes (OLED), and thin film photovoltaics. Founded in 2002 as Semzyme, Inc., the company rebranded to Cambrios Technologies Corporation in 2004 and is headquartered in Sunnyvale, California, with additional offices in Japan and Taiwan. Cambrios aims to leverage its nanostructured materials to improve the efficiency and capabilities of next-generation consumer devices.

IntraPace, Inc. specializes in the development and marketing of implantable devices aimed at treating obesity. Founded in 2001 and located in Mountain View, California, the company has created the abiliti system, which stimulates a satiety response to facilitate weight loss. This innovative device is based on technology commonly used in cardiac pacemakers and defibrillators, allowing for implantation through standard laparoscopic methods. Notably, the abiliti system does not alter the digestive system's anatomy and imposes no restrictions on a patient's dietary intake, making it a versatile option for individuals seeking weight management solutions.

Trubion Pharmaceuticals is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. Our product candidates are novel proteins known as single-chain polypeptides and are designed using our SMIPTM custom drug assembly technology.

PowderMed developed vaccines for the treatment of chronic infectious diseases and cancer. The company used DNA coated gold particles delivered by a needle-free injection device to stimulate a powerful and specific T cell immune response.

Ensemble Therapeutics Corporation is engaged in the discovery and development of small molecule therapies aimed at treating cancer and other serious diseases. The company focuses on creating innovative therapies, particularly in the field of immuno-oncology, targeting mechanisms such as Indoleamine 2, 3-dioxygenase 1 (IDO-1) and components of the ubiquitin proteasome system. Its pipeline includes treatments that inhibit apoptosis-promoting proteins, which can prevent tumor cell death, as well as targeting Cyclophilins that aid in protein folding. Founded in 2002 and based in Cambridge, Massachusetts, Ensemble Therapeutics aims to provide safe and effective treatment options by addressing previously inaccessible drug targets. The company changed its name from Ensemble Discovery Corporation in June 2010.

Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.

Mitralign is a privately held company based in a suburb of Boston, Massachusetts, focused on developing a catheter-based technology for the treatment of functional mitral regurgitation. The company has created an innovative system that mimics surgical annuloplasty by delivering surgical implants directly into the mitral annulus via a catheter. This process involves cinching the implants together to decrease the size of the mitral valve annulus and the valve opening. Mitralign's technology aims to provide a less invasive option for managing this life-threatening cardiac condition, enabling healthcare providers to effectively treat symptomatic functional mitral regurgitation through tissue-plication. The company is supported by prominent venture capitalists and has attracted investments from major cardiovascular device firms.

VaxInnate is a biotechnology company based in Cranbury, New Jersey, founded in 2002. The company specializes in developing vaccines aimed at combating diseases such as influenza, malaria, dengue, papillomavirus, and respiratory syncytial virus. VaxInnate employs a unique approach by genetically fusing vaccine antigens with bacterial protein flagellin, which enhances the immunogenicity and efficacy of the vaccines. This innovative method facilitates quicker patient treatment initiation and increases the likelihood of successful outcomes. Through its focus on healthcare and health diagnostics, VaxInnate aims to address significant public health challenges with its advanced vaccine solutions.

ZettaCore is at the forefront of molecular electronics, dedicated to creating advanced molecular materials tailored for the electronics industry. By utilizing innovative chemistry, the company enhances existing manufacturing processes, facilitating a shift towards improved performance while simultaneously reducing costs.

Enanta Pharmaceuticals is a biotechnology company based in Watertown, Massachusetts, dedicated to the discovery and development of small molecule drugs targeting viral infections and liver diseases. Founded in 1995, the company focuses on several key areas, including hepatitis C and B, non-alcoholic steatohepatitis, and respiratory syncytial virus. Notably, Enanta has developed glecaprevir, marketed under the names MAVYRET and MAVIRET, for the treatment of chronic hepatitis C virus. The company collaborates with Abbott Laboratories to advance compounds such as paritaprevir and glecaprevir, enhancing its portfolio of direct-acting antiviral inhibitors. Additionally, Enanta is exploring new antibiotics like EDP-420, aimed at treating community-acquired pneumonia and combating antibiotic resistance. The firm’s ongoing research efforts reflect a commitment to addressing significant medical needs in infectious diseases and liver health.

Accelerated Technologies, Inc. (ATI), a New York based partnership model for the creation and acceleration of cardiovascular devices.

Xanthus Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, acquisition, and commercialization of small-molecule therapeutics targeting cancer and autoimmune disorders. The company specializes in creating innovative treatments that address unmet medical needs in these critical areas. Through its focused approach, Xanthus Pharmaceuticals aims to advance healthcare solutions that improve patient outcomes and enhance the quality of life for those affected by these diseases.

Asterand Bioscience is a leading global provider of high-quality human tissue and human tissue-based research solutions, primarily aimed at drug discovery scientists. Established in 2006 through the merger of Asterand, a human tissue biorepository, and Pharmagene, a drug discovery company, Asterand has a strong heritage in human tissue procurement and characterization. The company focuses on accelerating the identification and validation of drug targets while enhancing the selection of drug candidates to increase the likelihood of clinical success. With offices in Detroit, Michigan, and Royston, United Kingdom, Asterand serves pharmaceutical, biotechnology, and diagnostic companies, as well as academic institutions, offering comprehensive research services that span from target identification to compound evaluation and drug safety.

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases.

AVEO Oncology is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing and marketing targeted therapies for cancer. Its lead product, tivozanib, marketed as FOTIVDA, is an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used for treating renal cell carcinoma (RCC). The company has completed a Phase III trial of tivozanib and is investigating its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, AVEO is developing Ficlatuzumab, an antibody targeting hepatocyte growth factor, currently in Phase II trials for several cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company also has preclinical products aimed at cachexia and pulmonary arterial hypertension. AVEO collaborates with various pharmaceutical companies to enhance its research and development efforts. Established in 2001, AVEO Oncology aims to address unmet medical needs in oncology through its innovative therapies.

Alantos Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule drugs targeting conditions such as osteoarthritis, inflammation, and type II diabetes. Established in 2002 and located in Cambridge, Massachusetts, the company specializes in innovative therapeutic approaches, including Dipeptidyl and Peptidase IV inhibitors. In addition to its core areas, Alantos explores various tissue remodeling pathways to address a range of medical issues, including rheumatoid arthritis, liver fibrosis, cardiovascular conditions, chronic wound healing, and cancer.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

BrainGate is a path to a better way of life for severely motor-impaired individuals. Through years of advanced research, BrainGate enables these people with the ability to communicate, interact and function through thought. (view video) BrainGate's mission is to further the advancement of this life-changing technology to promote wider adoption to help impaired individuals communicate and interact with society. For instance, the Cyberkenetics BrainGate Neural Interface is currently the subject of a pilot clinical trial being conducted under an Investigational Device Exemption (IDE) from the FDA. The system is designed to restore functionality for a limited, immobile group of severely motor-impaired individuals. It is expected that people using the BrainGate System will employ a personal computer as the gateway to a range of self-directed activities. These activities may extend beyond typical computer functions (e.g., communication) to include the control of objects in the environment such as a telephone, a television and lights.

Cohesive Technologies Inc. designs, manufactures, and markets breakthrough liquid chromatography (LC) solutions for the drug discovery, pharmaceutical, contract research, and clinical diagnostic industries. The company has developed patented technologies and a wide range of chromatographic products designed to significantly improve productivity by accelerating the separation, purification, and analysis of molecules in bioanalysis. With a strong depth of knowledge in column chemistry, applications, engineering, software development, and quality management, Cohesive Technologies leads the industry in the research, development, and production of LC technologies that accelerate the pace of customers' drug discovery and development efforts.

Sirna Therapeutics is a biotechnology company focused on developing therapies based on RNA interference (RNAi), a groundbreaking scientific discovery with the potential to transform disease treatment. By harnessing the capabilities of RNAi, Sirna Therapeutics aims to create innovative solutions that address various illnesses, positioning itself at the forefront of this emerging field. The company's commitment to advancing RNAi-based therapies highlights its role in the evolving landscape of medical treatment, with the goal of improving patient outcomes through targeted interventions.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of small molecule drugs aimed at addressing unmet medical needs in central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, the company is best known for NUPLAZID (pimavanserin), which is approved for treating hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA is also advancing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive therapy for schizophrenia, both of which are currently in Phase III clinical trials. Additionally, the company is exploring the use of pimavanserin for major depressive disorder. ACADIA maintains subsidiaries in Sweden and Denmark and is focused on expanding its portfolio of drug candidates, seeking to discover innovative therapies for various neurological and psychiatric conditions.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Hypnion is a neuroscience drug discovery and development company that specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness issues as well as circadian rhythm abnormalities. Founded in 2000 and based in Worcester, Massachusetts, Hypnion has developed a proprietary drug discovery platform known as SCORE-2004, which measures the effects of various drugs on sleep and wake parameters. The company has attracted attention in the pharmaceutical industry, culminating in its acquisition by Eli Lilly and Company.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

As of January 27, 2004, Percutaneous Valve Technologies was acquired by Edwards Lifesciences Corp. The company develops medical devices for delivering heart valves to treat late-stage aortic stenosis. Percutaneous Valve Technologies, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.